Comparing the aPL prevalence between a control population of 501 blood donors and stroke patients, we found statistically significant differences in the prevalence of IgG aB2GPI (0.2 vs. 2.0%, p = 0.008), IgM aB2GPI (0.2 vs. 4.1%, p < 0.001), IgA aB2GPI (1.0 vs. 20.0%, p < 0.001), IgM aCL (0.0 vs. 4.1%, p < 0.001), and IgG/IgM aPS/PT (1.2 vs. 7.8%, p < 0.001), respectively (Supplementary Table 2). This evidence concerns the gene CD40LG and stroke disorder.